Navigation Links
Study shows promise for new cancer-stopping therapy
Date:6/11/2009

Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.

MicroRNAs (miRNA) are a class of small RNA molecules that are highly expressed in normal tissues and are critical in gene expression and in maintaining normal cell development and cell balance. Dysfunction of miRNAs has been linked to multiple human diseases including schizophrenia, autism and cancer.

"The pattern of expression of miRNAs has emerged as critically useful information for understanding cancer development and could be used to establish prognosis and treatment responses," said Janaiah Kota, PhD, a postdoctoral scientist from Nationwide Children's.

In a study reported in Cell (June 12, 2009), the team of researchers employed a novel strategy to treat an important form of cancer. Studies targeted hepatocellular (liver) cancer (HCC), the third leading cause of cancer-related deaths. HCC is commonly associated with underlying liver abnormalities, such as hepatitis B and C infections and cirrhosis. HCC is difficult to treat since it is often diagnosed at an advanced stage and because its biologic composition makes the tumor highly resistant to current drug therapies. However, the research reported in Cell suggests that miRNA gene delivery may be a clinically viable therapy when delivered by a recombinant adeno-associated virus (AAV).

HCC expresses a reduced number of miRNAs, including miR-26a. By combining miRNA technology developed at Johns Hopkins University with the gene delivery expertise of Nationwide Children's Hospital, scientists were able to successfully deliver AAV carrying miR-26a to a mouse with established HCC. This gene therapy strategy inhibited growth of cancer cells and led to tumor reduction and cell death, without causing toxic side effects to the remainder of the liver. This demonstrates for the first time that therapeutic delivery of a miRNA in an animal can result in tumor suppression, without the need for specifically targeting the cancer causing oncogene.

"We are eagerly looking forward to applying this methodology to other tumor types in the laboratory and potentially bringing this approach forward for clinical testing in patients," said Jerry Mendell, MD, director, Center for Gene Therapy in The Research Institute at Nationwide Children's Hospital and a faculty member of The Ohio State University College of Medicine. "While there remains significant work to be done both in identifying such miRNAs and optimizing their delivery, our findings highlight the therapeutic promise of this approach."

The findings of therapeutic miRNA gene replacement in HCC has potential for applicability to other types of cancers, as well. The delivery and restoration of miRNA expression via AAV mediated gene transfer of the miRNA may be beneficial to a large number of cancer subtypes.

"This concept of replacing microRNAs that are expressed in high levels in normal tissues but lost in diseases hasn't been explored before," said Josh Mendell, M.D., Ph.D., an associate professor in the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. "Our work raises the possibility of a more general therapeutic approach that is based on restoring microRNAs to diseased tissues."


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@nationwidechildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Study finds segregation decreases access to surgical care for minorities
2. Kessler Foundation Research Center Study Provides Insight into One of the Most Challenging Symptoms Following a Traumatic Brain Injury
3. Kessler Foundation Research Center Study Provides Insight into One of the Most Challenging Symptoms Following a Traumatic Brain Injury
4. PAREXEL Enhances Study Start-Up and Recruitment Capabilities With Appointment of Dr. Lars-Olof Eriksson, Formerly With Merck
5. Want to Learn How to Testify? New Home Study Course by Practicing Physician Teaches Medical Malpractice Defendants and Physicians How to be Effective in Court
6. Morning Sickness Drug Gets Green Light in Study
7. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
8. New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes
9. New Jefferson study may redefine how a chronic auto-immune disease is diagnosed
10. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
11. Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: